← All trials
NCT04602117
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2020
- Primary completion
- Dec 1, 2021
- Completion date
- Jun 29, 2022
- First posted
- Oct 26, 2020
- Last posted
- Oct 26, 2020
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- QuantumLeap Healthcare CollaborativeLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.